SynthesisMolecular biology reports2025
Therapeutic evaluation of bone marrow mesenchymal stem cells for hepatitis virus infection: immunoregulation, anti-inflammatory effects, and clinical potential - a systematic review.
Synthesis in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Berberine-Pretreated Bone Marrow Mesenchymal Stem Cells Accelerate Skin Wound Healing in Rats With Burn Injuries.International wound journal · 2026Article
- pH-responsive Ni-MOF based nanocarriers with folic acid targeting for enhanced chemotherapeutic efficacy in breast cancer.RSC advances · 2026Article
- Application of stem cells in the precise diagnosis and treatment of liver diseases.World journal of gastroenterology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne kind of stem cell essential to regenerative medicine is mesenchymal stem cells (MSCs). The most common chronic viral infectious disease in the world, viral hepatitis, is characterized by potentially fatal liver inflammation brought on by hepatitis virus infections in the liver cells. Hepatitis B virus (HBV) infections can spread horizontally (via contaminated blood) or vertically (from mother to child). Hepatitis C Virus (HCV) is the main cause of chronic liver disease and is mainly spread by sharing needles, receiving unsterilized blood transfusions, and having intercourse with contaminated blood.
methodsThis study employs a systematic review design using the PRISMA method, screening 19 journals based on specific inclusion and exclusion criteria.
resultsExosomes from umbilical cord MSCs (UC-MSCs) effectively suppressed interleukin 1β, interleukin 6, and transforming growth factor β1 in an in vitro liver fibrosis model. They inhibited LX2 activation, reducing extracellular matrix proteins (COL I and α-SMA). The bone marrow MSC (BM-MSC) group showed a significantly higher 24-week survival rate than the standard medical therapy (SMT) group. MSCs secrete key anti-inflammatory cytokines mediating immunomodulatory effects and supporting regeneration through differentiation potential. Pretreating MSCs with various stimuli enhances therapeutic efficacy before liver transplantation. BM-MSCs improve liver function, reduce infections, and increase survival due to immunomodulatory and anti-inflammatory properties. Both allogeneic and autologous BM-MSC and UC-MSC transplants do not cause secondary liver cirrhosis related to chronic hepatitis B, but strict monitoring is necessary to prevent side effects like carcinogenesis and viral transmission. MSCs also influence angiogenesis and tumor cells by secreting growth factors.
conclusionBone Marrow Mesenchymal Stem Cells (BM-MSCs) and Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) demonstrate promising therapeutic efficacy against viral hepatitis infection through various mechanisms, including immunomodulation, anti-inflammatory effects, and regenerative potential. Vigilant monitoring for adverse effects is necessary to ensure safety in clinical use.
Indexed as
Identifiers
40788553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.